Trials / Completed
CompletedNCT05176509
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YH003 | YH003 will be administered intravenously over 60 minutes every 21-day cycle. |
| DRUG | YH001 | YH001 will be administered intravenously over 60 minutes every 21-day cycle. |
| DRUG | Pembrolizumab | Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle. |
Timeline
- Start date
- 2022-04-05
- Primary completion
- 2023-08-23
- Completion
- 2023-08-25
- First posted
- 2022-01-04
- Last updated
- 2025-01-06
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05176509. Inclusion in this directory is not an endorsement.